Related Experiment Videos
Pseudomyxoma peritonei
1Cancer Institute, Washington Hospital Center, DC 20010, USA.
Abstract:
Pseudomyxoma peritonei is a clinical entity that has lead to much confusion about its etiology, clinical manifestations, treatment, and prognosis. Pseudomyxoma peritonei is currently defined as a grade I mucinous adenocarcinoma that arises from a primary appendiceal adenoma. The clinical entity is defined by a redistribution phenomenon. This means that cancer cells from the appendix tumor are found localized at predetermined sites within the abdomen and pelvis but that the primary tumor may be small and inconspicuous. The small bowel is spared of mucinous tumor, while spaces beneath the hemidiaphragms and within the pelvis are filled by disease. The omentum is massively replaced by tumor in most patients. The disease, when treated by multiple surgical procedures, presents a median survival of approximately 2 years. Good results depend on early diagnosis and treatment before large volumes of disease and multiple surgical procedures lead to small bowel entrapment by tumor. In modern therapy using peritoneotomy procedures and intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil, the long-term survival at 10 years approaches 80 percent.
Insights
Pseudomyxoma peritonei, a rare cancer originating in the appendix, involves tumor spread within the abdomen. Modern treatments offer significantly improved long-term survival rates.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Pseudomyxoma peritonei (PMP) presents diagnostic and therapeutic challenges.
- It is characterized by mucinous adenocarcinoma, often originating from an appendiceal adenoma.
- PMP involves tumor cell redistribution within the abdomen and pelvis, sparing the small bowel.
Purpose of the Study:
- To clarify the etiology, clinical manifestations, treatment, and prognosis of pseudomyxoma peritonei.
- To highlight the importance of early diagnosis and intervention.
- To evaluate the efficacy of modern therapeutic approaches.
Main Methods:
- Review of clinical data and treatment outcomes for pseudomyxoma peritonei.
- Analysis of the "redistribution phenomenon" characteristic of PMP.
- Evaluation of outcomes with traditional surgical procedures versus modern peritoneotomy and intraperitoneal chemotherapy.
Main Results:
- Traditional surgical treatment yields a median survival of approximately 2 years.
- Early diagnosis and treatment are crucial to prevent complications like small bowel entrapment.
- Modern therapy with peritoneotomy and intraperitoneal chemotherapy (mitomycin C, 5-fluorouracil) shows a 10-year survival approaching 80%.
Conclusions:
- Pseudomyxoma peritonei requires a thorough understanding of its unique spread patterns.
- Aggressive surgical management combined with targeted intraperitoneal chemotherapy significantly improves patient survival.
- The prognosis for PMP has dramatically improved with advancements in treatment modalities.